Objective: The objective of this study was to assess the surgical, oncological and short-term functional outcomes in patients undergoing salvage robot-assisted radical prostatectomy (SRARP) for the treatment of radiation-resistant prostate cancer. Patients and Methods: The records of 3,500 men who underwent RARP from February 2006 to July 2011 were retrospectively reviewed. All peri- and postoperative data were recorded prospectively in our database. A total of 13 patients (0.37%) who had undergone SRARP for the treatment of radiation-resistant prostate cancer were identified. Results: The primary treatment was external beam radiotherapy in 7 patients (53.8%) and brachytherapy in 6 patients (46.2%). The interval from radiotherapy to biochemical recurrence (BCR) varied from 12 to 108 months (median 48.9). Neurovascular bundle preservation was performed in 3 patients (23.1%). No intraoperative or major complications were encountered. Minor complications were encountered in 4 patients (30.7%). At 12 months, 7 patients were continent (53.8%), 3 exhibited mild incontinence (23.1%) and 3 (23.1%) were incontinent. Regarding potency, none of the patients were potent at 6 months, but 3 patients (23.1%) were potent at 1 year. Regarding BCR, 3 of the patients (23.1%) never reached a prostate-specific antigen nadir of zero, and during the follow-up period only 3 patients (23.1%) exhibited BCR. No disease-specific mortality was evident during follow-up. Conclusions: Although early in its development, it appears that SRARP is technically feasible and offers satisfactory surgical, oncological and short-term functional outcomes.

Cupps RE, Utz DC, Fleming TR, Carson CC, Zincke H, Myers RP: Definitive radiation therapy for prostatic carcinoma: Mayo clinic experience. J Urol 1980;124:855-859.
Gheiler EL, Tefilli MV, Tiguert R, Grignon D, Cher ML, Sakr W, Pontes JE, Wood DP Jr: Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 1998;51:789-795.
Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR; Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE): Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 2008;112:307-314.
Bianco FJ Jr, Scardino PT, Stephenson AJ, DiBlasio CJ, Fearn PA, Eastham JA: Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:448-453.
Stephenson AJ, Eastham JA: Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005;23:8198-8203.
Touma NJ, Izawa JI, Chin JL: Current status of local salvage therapies following radiation failure for prostate cancer. J Urol 2005;173:373-379.
Ward JF, Sebo TJ, Blute ML, Zincke H: Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 2005;173:1156-1160.
Sanderson KM, Penson DF, Cai J, Groshen S, Stein JP, Lieskovsky G, Skinner DG: Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol 2006;176:2025-2031.
Ward JF, Pagliaro LC, Pisters LL: Salvage therapy for radiorecurrent prostate cancer. Curr Probl Cancer 2008;32:242-271.
Pontes JE, Montie J, Klein E, Huben R: Salvage surgery for radiation failure in prostate cancer. Cancer 1993;71(suppl 3):976-980.
Grossfeld GD, Li YP, Lubeck DP, Broering JM, Mehta SS, Carroll PR: Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol 2002;168:530-535.
Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-4456.
Van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O, Ingelsson E, Lambe M, Stattin P, Holmberg L: Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol 2010;11:450-458.
Stephenson AJ, Scardino PT, Bianco FJ Jr, DiBlasio CJ, Fearn PA, Eastham JA: Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 2004;172:2239-2243.
Vallancien G, Gupta R, Cathelineau X, Baumert H, Rozet F: Initial results of salvage laparoscopic radical prostatectomy after radiation failure. J Urol 2003;170:1838-1840.
Liatsikos E, Bynens B, Rabenalt R, Kallidonis P, Do M, Stolzenburg JU: Treatment of patients after failed high intensity focused ultrasound and radiotherapy for localized prostate cancer: salvage laparoscopic extraperitoneal radical prostatectomy. J Endourol 2008;22:2295-2298.
Ahallal Y, Shariat SF, Chade DC, Mazzola C, Reuter VE, Sandhu JS, Laudone VP, Touijer KA, Guillonneau BD: Pilot study of salvage laparoscopic prostatectomy for the treatment of recurrent prostate cancer. BJU Int 2011;108:724-728.
Ficarra V, Cavalleri S, Novara G, Aragona M, Artibani W: Evidence from robot-assisted laparoscopic radical prostatectomy: a systematic review. Eur Urol 2007;51:45-56.
Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, Guazzoni G, Guillonneau B, Menon M, Montorsi F, Patel V, Rassweiler J, Van Poppel H: Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 2009;55:1037-1063.
Jamal K, Challacombe B, Elhage O, Popert R, Kirby R, Dasgupta P: Successful salvage robotic-assisted radical prostatectomy after external beam radiotherapy failure. Urology 2008;72:1356-1358.
Boris RS, Bhandari A, Krane LS, Eun D, Kaul S, Peabody JO: Salvage robotic-assisted radical prostatectomy: initial results and early report of outcomes. BJU Int 2009;103:952-956.
Eandi JA, Link BA, Nelson RA, Josephson DY, Lau C, Kawachi MH, Wilson TG: Robotic assisted laparoscopic salvage prostatectomy for radiation resistant prostate cancer. J Urol 2010;183:133-137.
Kaouk JH, Hafron J, Goel R, Haber GP, Jones JS: Robotic salvage retropubic prostatectomy after radiation/brachytherapy: initial results. BJU Int 2008;102:93-96.
Chauhan S, Patel MB, Coelho R, Liss M, Rocco B, Sivaraman AK, Palmer KJ, Coughlin GD, Ferrigni RG, Castle EP, Ahlering TE, Parra-Davila E, Patel VR: Preliminary analysis of the feasibility and safety of salvage robot-assisted radical prostatectomy after radiation failure: multi-institutional preoperative and short-term functional outcomes. J Endourol 2011;25:1013-1019.
Strope SA, Coelho M, Wood DP, Hollenbeck BK: Robot-assisted salvage prostatectomy: evaluation of initial patient reported outcomes. J Endourol 2010;24:425-427.
Hartford AC, Palisca MG, Eichler TJ, Beyer DC, Devineni VR, Ibbott GS, Kavanagh B, Kent JS, Rosenthal SA, Schultz CJ, Tripuraneni P, Gaspar LE; American Society for Therapeutic Radiology and Oncology; American College of Radiology: American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT). Int J Radiat Oncol Biol Phys 2009;73:9-14.
Witt JH, Zugor V, Wagner C, Schutte A, Labanaris AP: Robot-assisted radical prostatectomy; in Meinhold-Heerlein, I (ed): Laparoscopy - An Interdisciplinary Approach. InTech, 2011. Available from: www.intechopen.com/articles/show/title/robot-assisted-radical-prostatectomy. ISBN 978-953-307-299-9.
Dindo D, Demartines N, Clavien PA: Classification of surgical complications: a new proposal with evaluation in a cohort of 6,336 patients and results of a survey. Ann Surg 2004;240:205-213.
Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM: Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319-326.
Guillonneau B, Vallancien G: Laparoscopic radical prostatectomy: the Montsouris technique. J Urol 2000;163:1643-1649.
Kuban DA, el-Mahdi AM, Schellhammer PF: Effects of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. Urology 1987;30:420-426.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.